TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) Income Tax Expense (Benefit) USD 2010 - 2024

Historical data

Taxonomy & unit
us-gaap: USD
Description
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Summary
Teva Pharmaceutical Industries Ltd quarterly/annual Income Tax Expense (Benefit) history and growth rate from 2010 to 2024.
  • Teva Pharmaceutical Industries Ltd Income Tax Expense (Benefit) for the quarter ending March 31, 2024 was -$52 M, a 174% decline year-over-year.
  • Teva Pharmaceutical Industries Ltd Income Tax Expense (Benefit) for the twelve months ending March 31, 2024 was -$40 M, a 94% increase year-over-year.
  • Teva Pharmaceutical Industries Ltd annual Income Tax Expense (Benefit) for 2023 was -$7 M, a 98.9% increase from 2022.
  • Teva Pharmaceutical Industries Ltd annual Income Tax Expense (Benefit) for 2022 was -$643 M, a 405% decline from 2021.
  • Teva Pharmaceutical Industries Ltd annual Income Tax Expense (Benefit) for 2021 was $211 M.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Quarterly (USD)
Income Tax Expense (Benefit), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 -$40 M -$52 M -$33 M -174% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-08
Q4 2023 -$7 M $40 M -$109 M -73.2% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-12
Q3 2023 $102 M -$12 M -$119 M -111% Jul 1, 2023 Sep 30, 2023 10-K 2024-02-12
Q2 2023 $221 M -$16 M +$884 M +98.2% Apr 1, 2023 Jun 30, 2023 10-K 2024-02-12
Q1 2023 -$663 M -$19 M -$21 M -1050% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-08
Q4 2022 -$642 M $149 M +$174 M Oct 1, 2022 Dec 31, 2022 10-K 2024-02-12
Q3 2022 -$816 M $107 M +$31 M +40.8% Jul 1, 2022 Sep 30, 2022 10-K 2024-02-12
Q2 2022 -$847 M -$900 M -$998 M -1018% Apr 1, 2022 Jun 30, 2022 10-K 2024-02-12
Q1 2022 $151 M $2 M -$60 M -96.8% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-10
Q4 2021 $211 M -$25 M -$4 M -19% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-12
Q3 2021 $215 M $76 M +$60 M +375% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 $155 M $98 M +$202 M Apr 1, 2021 Jun 30, 2021 10-Q 2022-07-27
Q1 2021 -$47 M $62 M +$121 M Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-03
Q4 2020 -$168 M -$21 M +$98 M +82.4% Oct 1, 2020 Dec 31, 2020 10-K 2023-02-10
Q3 2020 -$266 M $16 M +$5 M +45.5% Jul 1, 2020 Sep 30, 2020 10-Q 2021-10-27
Q2 2020 -$271 M -$104 M +$75 M +41.9% Apr 1, 2020 Jun 30, 2020 10-Q 2021-07-28
Q1 2020 -$346 M -$59 M -$68 M -756% Jan 1, 2020 Mar 31, 2020 10-Q 2021-04-28
Q4 2019 -$278 M -$119 M +$20 M +14.4% Oct 1, 2019 Dec 31, 2019 10-K 2022-02-09
Q3 2019 -$298 M $11 M +$37 M Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05
Q2 2019 -$335 M -$179 M -$103 M -136% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-05
Q1 2019 -$232 M $9 M -$37 M -80.4% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-07
Q4 2018 -$195 M -$139 M +$1.33 B +90.6% Oct 1, 2018 Dec 31, 2018 10-K 2021-02-10
Q3 2018 -$1.53 B -$26 M +$468 M +94.7% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-07
Q2 2018 -$2 B -$76 M -$54 M -245% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-07
Q1 2018 -$1.94 B $46 M -$8 M -14.8% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-02
Q4 2017 -$1.93 B -$1.47 B -$1.53 B -2681% Oct 1, 2017 Dec 31, 2017 10-K 2020-02-21
Q3 2017 -$405 M -$494 M -$701 M -339% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-01
Q2 2017 $296 M -$22 M -$51 M -176% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-02
Q1 2017 $347 M $54 M -$174 M -76.3% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-03
Q4 2016 $521 M $57 M -$192 M -77.1% Oct 1, 2016 Dec 31, 2016 10-K 2018-02-12
Q3 2016 $713 M $207 M +$14 M +7.25% Jul 1, 2016 Sep 30, 2016 6-K 2017-11-02
Q2 2016 $699 M $29 M -$59 M -67% Apr 1, 2016 Jun 30, 2016 6-K 2017-08-03
Q1 2016 $758 M $228 M +$124 M +119% Jan 1, 2016 Mar 31, 2016 6-K 2017-05-11
Q4 2015 $634 M $249 M +$63 M +33.9% Oct 1, 2015 Dec 31, 2015 10-K 2018-02-12
Q3 2015 $571 M $193 M +$33 M +20.6% Jul 1, 2015 Sep 30, 2015 6-K 2016-11-15
Q2 2015 $538 M $88 M -$14 M -13.7% Apr 1, 2015 Jun 30, 2015 6-K 2016-08-04
Q1 2015 $552 M $104 M -$39 M -27.3% Jan 1, 2015 Mar 31, 2015 6-K 2016-05-09
Q4 2014 $591 M $186 M +$72 M +63.2% Oct 1, 2014 Dec 31, 2014 20-F 2017-02-15
Q3 2014 $519 M $160 M +$148 M +1233% Jul 1, 2014 Sep 30, 2014 6-K 2015-10-29
Q2 2014 $371 M $102 M +$324 M Apr 1, 2014 Jun 30, 2014 6-K 2015-07-30
Q1 2014 $47 M $143 M +$90 M +170% Jan 1, 2014 Mar 31, 2014 6-K 2015-04-30
Q4 2013 -$43 M $114 M +$224 M Oct 1, 2013 Dec 31, 2013 20-F 2016-02-11
Q3 2013 -$267 M $12 M +$69 M Jul 1, 2013 Sep 30, 2013 6-K 2014-10-30
Q2 2013 -$336 M -$222 M -$261 M -669% Apr 1, 2013 Jun 30, 2013 6-K 2014-07-31
Q1 2013 -$75 M $53 M +$62 M Jan 1, 2013 Mar 31, 2013 6-K 2014-05-02
Q4 2012 -$137 M -$110 M -$128 M -711% Oct 1, 2012 Dec 31, 2012 20-F 2015-02-09
Q3 2012 -$9 M -$57 M -$90 M -273% Jul 1, 2012 Sep 30, 2012 6-K 2013-10-31
Q2 2012 $81 M $39 M +$12 M +44.4% Apr 1, 2012 Jun 30, 2012 6-K 2013-08-01
Q1 2012 $69 M -$9 M -$58 M -118% Jan 1, 2012 Mar 31, 2012 6-K 2013-05-02
Q4 2011 $127 M $18 M +$71 M Oct 1, 2011 Dec 31, 2011 20-F 2014-02-10
Q3 2011 $56 M $33 M -$100 M -75.2% Jul 1, 2011 Sep 30, 2011 6-K 2012-11-01
Q2 2011 $156 M $27 M -$91 M -77.1% Apr 1, 2011 Jun 30, 2011 6-K 2012-08-02
Q1 2011 $247 M $49 M -$36 M -42.4% Jan 1, 2011 Mar 31, 2011 6-K 2012-05-09
Q4 2010 $283 M -$53 M Oct 1, 2010 Dec 31, 2010 20-F 2013-02-12
Q3 2010 $133 M Jul 1, 2010 Sep 30, 2010 6-K 2011-11-02
Q2 2010 $118 M Apr 1, 2010 Jun 30, 2010 6-K 2011-07-28
Q1 2010 $85 M Jan 1, 2010 Mar 31, 2010 6-K 2011-05-11
* An asterisk sign (*) next to the value indicates that the value is likely invalid.